NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Wuhan Wansheng Biotechnology

Published 12 Nov 2026. 41-page investigative report on who is behind Wuhan Wansheng Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 266 Finnrick lab tests, Wuhan Wansheng Biotechnology posts 184 pass / 82 fail — an overall pass rate of 69%. The signal is sharply product-specific rather than vendor-wide. Retatrutide and Tirzepatide test strongly enough to be the more defensible WWB choices, while CJC-1295 and Tesamorelin define the weak end. Ratings also compress under stricter grading, and the full appendix carries the product-by-product breakdown.

The non-lab findings are a buyer-authentication problem, not a simple real-versus-fake story. The operating trail runs through WS LAB / Hepius-era infrastructure and a current official-looking storefront, but registry work found only a 2021 Wuhan address-hosting notice for the Chinese name and did not identify the UBO, legal representative, or named quality-release authority.

The trust layer performs poorly. Eight displayed Janoshik-style reports failed Janoshik’s own verification, and the verify links route through vendor-controlled lookalike hostnames. Searchers also encounter WWB-branded clone storefronts, a self-hosted Trustpilot-style reviews page, and synthetic lab/review properties whose About pages borrowed Finnrick-linked identities.

For a buyer already considering WWB, the practical read is narrow: authenticate the domain and handle before payment, distrust badges and review pages that do not verify at the source, and do not borrow Retatrutide/Tirzepatide performance for weaker lines. Forum reports of backlog and refund friction add medium fulfillment risk; China-origin peptide/API shipments remain seizure-exposed without any WWB-specific FDA or CBP action found.

Inside the full report:

  • Per-product Finnrick pass/fail rates, spark grids and methodology-divergence charts for all 12 products
  • Direct Janoshik verification results for the displayed WWB report task/key pairs
  • Domain-by-domain authentication map covering official, predecessor, clone and unverified WWB storefronts
  • Infrastructure analysis of the NICENIC/Cloudflare fake lab, review and directory clusters
  • Chinese registry/address-hosting record, UBO gaps, fulfillment reports and customs context

Risk assessment

  • Impersonation and brand-confusion risk — high: At least eight WWB-branded lookalike domains were live or recently active; wuhanwanshengbio.co uses @gemmaconway, and the official site lacks adequate anti-counterfeit or authorized-channel controls.
  • COA and test-report authenticity risk — high: Eight of eight displayed Janoshik-style reports failed Janoshik verification, and the site’s verify links use vendor-controlled lookalike subdomains.
  • Reputation-manipulation risk — high: The official site hosts a Trustpilot lookalike while the real Trustpilot profile is removed; fake lab/review sites reuse Finnrick-linked identities and shared WWB datasets.
  • Product-quality risk — weak WWB lines — high: Finnrick ratings are poor for Tesamorelin 32.04%, CJC-1295 28.93%, BPC-157 42.81% and TB-500 43.55%.
  • Product-quality risk — middle WWB lines — medium: Cagrilintide 56.85%, Ipamorelin 64.7%, Semaglutide 65.21%, Melanotan II 64.21% and PT-141 61.62% should not inherit the stronger Retatrutide/Tirzepatide signal.
  • Fulfillment and refund risk — medium: Community reports describe September 2026 orders still unshipped in late October, refunds unpaid and a Gary account banned; confidence is medium because these are forum reports.
  • Ownership and accountable-QA transparency concern — medium: UBO remains unresolved; no current registry extract, legal representative, shareholder list, ICP filing or named QA/batch-release authority was recovered.
  • Affiliate-promotion risk — medium: The official site offers 10% affiliate commissions and code WWB5 while synthetic review and directory sites promote WWB-branded domains without credible independent disclosure.
  • Customs-seizure risk for China-origin peptide/API shipments — medium: FDA Import Alert 66-80 broadened in 2026 and CBP reported 5,000+ peptide intercepts from China; this is route-specific and not a WWB-specific enforcement action.